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ABSTRACT
Disseminated triple negative breast cancer (TNBC) is an incurable disease with 
limited therapeutic options beyond chemotherapy. Therefore, identification of druggable 
vulnerabilities is an important aim. Protein kinases play a central role in cancer and 
particularly in TNBC. They are involved in many oncogenic functions including migration, 
proliferation, genetic stability or maintenance of stem-cell like properties. In this article 
we describe a novel multi-kinase inhibitor with antitumor activity in this cancer subtype. 
EC-70124 is a hybrid indolocarbazole analog obtained by combinatorial biosynthesis 
of Rebeccamycin and Staurosporine genes that showed antiproliferative effect and in 
vivo antitumoral activity. Biochemical experiments demonstrated the inhibition of the 
PI3K/mTOR and JAK/STAT pathways. EC-70124 mediated DNA damage leading to 
cell cycle arrest at the G2/M phase. Pathway analyses identified several deregulated 
functions including cell proliferation, migration, DNA damage, regulation of stem cell 
differentiation and reversion of the epithelial-mesenchymal transition (EMT) phenotype, 
among others. Combination studies showed a synergistic interaction of EC-70124 
with docetaxel, and an enhanced activity in vivo. Furthermore, EC-70124 had a good 
pharmacokinetic profile. In conclusion these experiments demonstrate the antitumor 
activity of EC-70124 in TNBC paving the way for the future clinical development of this 
drug alone or in combination with chemotherapy.
INTRODUCTION
Breast cancer is a heterogeneous disease as 
demonstrated at a genomic level with the description 
of different breast cancer subtypes with independent 
clinical outcome [1, 2, 3, 4]. Among them, triple negative 
breast cancer (TNBC) lacks the expression of hormone 
receptors and HER2 overexpression, representing 15% 
of all breast tumors [5]. It is associated with a specific 
pattern of tumor relapse and an increased sensitivity to 
chemotherapy [6, 7]. TNBC has been classified into 
several subtypes with different sensitivities to treatment 
[8]. Although the identification of subgroups in triple 
negative cancer represents a major advance, unfortunately 
the implementation of this classification for therapeutic 
purposes is unclear [9]. Indeed available therapeutic 
options for patients with TNBC are restricted to standard 
treatment with chemotherapy [9].
Membrane receptors and downstream kinase 
mediators are involved in the regulation of many cellular 
activities associated with human transformation [10, 11], 
including survival, response to DNA damage, migration, 
morphogenesis, cell adhesion, stem cell differentiation or 
proliferation, among others [12]. TNBC is a tumor subtype 
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characterized by a high metastatic capacity, presence of 
stem cell precursors and a high proliferation rate [13, 
14]. Similarly, alterations of the DNA repair machinery 
seem to be of great significance in this cancer [15, 16]. 
This breast cancer subgroup is enriched with genes 
associated to DNA damage response, when evaluated by 
gene expression analyses [8]. There is also an increased 
presence of somatic and acquired mutations in DNA 
repair genes, mainly BRCA1 and BRCA2, involved in the 
homologous recombination (HR) repair mechanism [15, 
16]. Protein kinases also participate in the regulation and 
maintenance of genetic integrity [17].
Using human samples, our group and others evaluated 
the kinase profile of TNBCs, observing that a number of 
these proteins are constitutively activated [18, 19]. These 
included receptors and downstream mediators like ERK1/2, 
SRC, ERK5, STAT1 and STAT3 [19]. Of particular 
relevance was the activation of components of the PI3K/
mTOR/AKT pathway such as pS6 or AKT. Interestingly, 
inhibition of the PI3K/mTOR route produced a proliferative 
arrest in cellular models and a growth reduction in tumors 
implanted in xenografted animals or generated using 
transgenic models [19]. Sequencing approaches have also 
confirmed the relevance of this route in TNBC suggesting 
that the PI3K/mTOR pathway is a significant druggable 
oncogenic alteration in this disease [20].
The translation of these findings to the clinical 
setting has been occasionally disappointing. Clinical 
studies evaluating drugs targeting individual proteins 
or pathways have shown negative results suggesting 
that therapeutic strategies should be designed to inhibit 
a number of key oncogenic nodes [21, 22], rather than 
individual kinases alone. This was the case for the 
negative results when targeting the Epidermal Growth 
Factor Receptor (EGFR) in TNBC [22]. Based on the 
global importance of protein kinases in TNBC [23], the 
development of novel polypharmacology inhibitors that 
could hit relevant signalling pathways simultaneously, is 
a desirable goal.
EC-70124 is a hybrid indolocarbazole analog 
obtained by combinatorial biosynthesis of Rebeccamycin 
and Staurosporine gene pathways and produced by 
fermentation [24]. EC-70124 shows antitumor activity in 
a wide range of solid tumors through the inhibition of key 
signaling nodes at a nanomolar range [24]. EC-70124 has 
completed its safety evaluation in preclinical models and 
is starting its clinical development [24].
In the present study we evaluated the anti-tumor 
properties of this novel multi-kinase inhibitor in TNBC. 
We observed that EC-70124 is active against a panel of 
TNBC cells and in xenografted mice. EC-70124 inhibited 
relevant pathways in TNBC including the PI3K/mTOR 
pathway or STAT1/3. In addition, it modified several 
cellular functions including DNA damage, migration and 
stem cell differentiation, among others. Finally EC-70124 
synergized in vivo and in vitro with taxanes.
RESULTS
Antitumor effect of EC-70124 in TNBC
Figure 1A represents the chemical structure of EC-
70124. To explore the antitumor effect of this compound 
on TNBC, we used a panel of representative cell lines 
including HS578T, BT549, MDA-MB-231 and HCC3153. 
In these cells, treatment with EC-70124 inhibited MTT 
metabolization in a dose and time dependent manner 
(Figure 1B, 1C). As shown in Figure 1C the IC50 values 
for different time points were in the nanomolar range.
The clonogenic cell survival assay determines the 
ability of a cell to proliferate indefinitely, thereby retaining 
its reproductive ability to form a large colony or a clone. 
Treatment with EC-70124 strongly decreased the number of 
colonies formed at 10 days in HS578T, BT549 and MDA-
MB-231 (Figure 1D).
The effect of EC-70124 on three-dimensional 
growth were also assessed. For this purpose, we cultured 
HS578T, BT549 and MDA-MB-231 in matrigel, a 
semisolid media where cells grow forming spherical 
structures. Treatment with the drug strongly decreased 
the diameter of these spheres (Figure 1E) (control vs 
treatment, mean diameter and SD = 2.1 +/−0.15 vs 0.9 
+/−0.14 and 2.6 +/−0.1 vs 1 +/−0.14, and 3 +/−0.17 
vs 1 +/−0.18 for HS578T, BT549 and MDA-MB-231, 
respectively). Similarly, a reduction in the total 
number of colonies per plate was observed. This data 
demonstrates the effect of EC-70124 on the inhibition of 
cell growth in 3D cultures.
Finally, to investigate the in vivo effect of EC-70124 
on the growth of TNBC, we implanted MDA-MB-231 into 
the mammary fat pad of mice. Treatment with EC-70124 
(18 mg/kg i.v. every 3 days) showed anti-tumor effect 
compared to control (Figure 1F). The mean tumor volume 
(mm3) measured every 3 days was significantly higher in 
the control versus the treated group (day 22; control vs 
treated, mean volume 826 vs 369 mm3, SD +/−376 and 
+/−121.5, respectively; p = 0.036). We also measured the 
drug effect on body weight and other toxicity parameters 
as mice behavior or skin modifications. We did not find 
differences between control vs treated animals in any of 
these parameters (Supplementary Figure S1A).
Effect of EC-70124 on the TNBC kinase profile
To evaluate the effect of EC-70124 on several 
protein kinases in HS578T and BT549, we used two 
phospho-kinase array kits. EC-70124 was able to inhibit 
downstream components of the PI3K/AKT pathway 
including AKT (phosphorylated at T308 and S473) and 
pS6 (Figure 2A). We confirmed these results by Western-
blot analyses, except for the inhibition of pAKT-S473 in 
BT549 (Figure 2B). Similarly, p-Stat3 and p-Stat1 were 
also inhibited in HS578T and BT549 (Figure 2A, 2B). 
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Figure 1: Chemical structure of EC-70124 and anti-tumor action in vitro and in vivo. A. Representation of the chemical structure 
of EC-70124. B, C. Effect of EC-70124 on cell proliferation in HS578T, BT549, MDA-MB-231 and HCC3153. (B) Cells were cultured in 
DMEM and RPMI + 10% FBS in the presence of EC-70124 at a concentration range of 0.1–2 μM, in a dose-dependent manner, for 72 hours 
(C) The inhibitory effect, as the IC50, was calculated after 24, 48, 72 hours of drug incubation using MTT assays. Metabolization of MTT in 
viable cells was determined by spectrophotometry. The mean absorbance values of untreated cell lines (controls) were taken as 100%. D. Action 
of EC-70124 on colony formation in HS578T, BT549, MDA-MB-231. Cells were treated with EC-70124 (300 nM) for 24 h. Data are 
represented as the mean ± s.d. of triplicate experiments. Student’s test was used to calculate statistical significance: **p < 0.005, ***p < 0.001. 
E. Effect of EC-70124 on cell growth in semi-solid medium in HS578T, BT549 and MDA-MB-231. Cells were plated in 48 multiwell plates 
and grown in medium containing matrigel for 7 days in the presence of EC-70124 (500 nM). All images were taken at ×20 magnification. The 
quantitation of sphere diameter was performed manually by tracing a straight line across the sphere diameter of untreated cells (controls) and 
scoring its value as arbitrary length units. Total number of colonies per plate was manually counted. * Indicates a P < 0.05, ** indicates p < 0.005, 
and *** indicates p < 0.001 with respect to each control. F. Growth inhibition of human breast tumor xenografts in female BALB/c nude mice by 
treatment with EC-70124. Animals were randomly assigned to two groups and received either intravenous EC-70124 (18 mg/kg/3 days/i.v.) or 
vehicle. The p-value (* < 0.05) was calculated on day 22 comparing the tumor volume of both groups using the Student’s t-test. Bars indicate s.d.
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Of note, we were unable to confirm by Western-blot the 
inhibition of pErk1/2 observed in the kinase array.
To have a global view of the kinase activity of 
EC-70124, a 169 kinase panel using a mobility shift 
assay at 1mM ATP concentration for all kinases (well 
above their Km value and similar to the intracellular ATP 
concentration) was profiled by Carna Biosciences (Kobe, 
Japan). Figure 2C shows a list of kinases with various 
degrees of inhibition at 100 nM EC-70124. Some of the 
RTKs for which EC-70124 showed inhibitory effect in the 
kinase assay were not affected in HS578T and BT549. 
This effect although surprising could be explained by the 
limited phosphorylated expression of RTK in cell lines 
in basal conditions compared with other downstream 
mediators (Supplementary Figure S1B).
EC-70124 induces G2/M arrest
To gain insights into the mechanism of the 
antiproliferative action of EC-70124 we explored the 
effect of the drug on cell cycle and apoptosis. Propidium 
iodide staining of HS578T, BT549 and MDA-MB-231 
showed that EC-70124 induced accumulation of cells in 
G2/M phase (Figure 3A, 3B), an effect which was more 
pronounced at 24 h (15%, 22% and 18% increase for 
HS578T, BT549 and MDA-MB-231, respectively). Next, 
we used Annexin V staining to explore the effect of EC-
70124 on apoptosis, observing an increase at 48 hours, 
more evident in HS578T (Figure 3C).
Induction of apoptosis can be caspase-dependent 
or caspase-independent. To explore the mechanism 
of cell death induced by the drug we treated HS578T, 
BT549 and MDA-MB-231 with the pancaspase inhibitor 
Z-VAD-FMK and evaluated Annexin V staining at 
48 hours. We found no modifications in apoptosis with 
and without the presence of the pancaspase inhibitor in 
HS578T and BT549, and a small decrease in apoptosis 
in MDA-MB-231, showing that the proapoptotic effect is 
mainly independent of caspases (Figure 3D). In addition, 
treatment with EC-70124 did not produce cleavage of 
PARP at different time points (Figure 3E).
EC-70124 modifies different pathways
In parallel to the biochemical analyses, we also 
performed mRNA expression profiling studies. For this 
purpose, we treated MDA-MB-231 with EC-70124 using 
the IC50, and extracted mRNA at 24 hours. A gene set 
enrichment analysis (GSEA) based on a comprehensive 
pathway database (4319 gene sets) identified 938 gene 
sets affected by the drug treatment (p-value <= 0.025 
and FDR <= 0.25), representing diverse biological 
functions (Supplementary Table S1 –GSEA_table). A 
network was created and grouped these gene-sets in 166 
functional modules. Based on the gene overlap between 
these modules (map layout) as well as the functional 
annotations, it was possible to organize and summarize 
the results in 4 main categories (Figure 4A, 4B, 4C and 
4D): gene sets associated with DNA damage response, 
translation and regulation of gene expression were up-
regulated as shown in Figure 4A; gene sets down-regulated 
in the treated samples included functions or pathways such 
as: cell mesenchymal development/morphogenesis and 
regulation of stem cell differentiation (Figure 4B); EMT 
related glycan metabolism (Figure 4C); cell adhesion, 
extracellular matrix, migration and proliferation (Figure 
4D). A list of selected modified genes included in these 
gene sets is shown in Supplementary Table S2.
Next, we explored whether some of the observed 
functions could be confirmed with cellular and bio-
chemical experiments. As shown in Figure 5A treatment 
with EC-70124 reduced cell migration in MDA-MB-231, 
BT549 and HS578T. Similarly we confirmed the reduced 
expression of CD44, ALDH1, CD49f and CD133 after 
treatment with EC-70124, all representative stem cell 
markers associated with the “regulation of stem cell 
differentiation” pathway (Figure 5B).
EC-70124 induces DNA damage
Among causes that produce an increase of DNA 
repair genes and an arrest at G2/M phase is the presence 
of lesions in the DNA and the subsequent intent to repair 
and maintain its integrity [17]. In the gene enrichment 
analyses we observed that EC-70124 induced genes 
related to DNA repair mechanism at 24 hours that were 
also confirmed by qPCR (PRMT6, RAD52, GADD45A, 
XPA, LIG4, FANCF, BRCA1, BRCA2, DDB2) (Figure 
5C, 5D). Therefore, to investigate if EC-70124 induced 
DNA damage, we analyzed the levels of phosphorylated 
γH2AX. It is known that this protein is required for 
checkpoint-mediated cell cycle arrest and DNA repair 
following double-stranded DNA breaks [17, 25]. 
Treatment with EC-70124 in HS578T, BT549 and MDA-
MB-231 showed an increase in the phosphorylated levels 
of γH2AX at early time points (Figure 5E). In response 
to DNA DSBs, ATM phosphorylates multiple substrates 
including, Chk2, p53, and γH2AX [17, 26]. We observed 
that EC-70124 induced the phosphorylation of p53 and 
Chk2 (Figure 5E) confirming the induction of DNA 
damage.
EC-70124 synergizes with standard of care 
chemotherapies
As success in cancer therapy is based on drug 
combinations, we investigated the effect of EC-70124 
in association with chemotherapies used in the clinical 
setting for triple negative tumors; including vinorelbine, 
docetaxel, and carboplatin. We did first a dose response 
curve with these chemotherapies to select doses around 
the IC50 (data not shown). Next we combined EC-70124 
Oncotarget27927www.impactjournals.com/oncotarget
Figure 2: Effect of EC-70124 on signaling routes and kinase inhibitory profile. A. Expression of activated signaling proteins 
in BT549 and HS578T; and effect of EC-70124 on their phosphorylated status. Cell lysates were examined for the phosphorylation of a 
panel of eleven intracellular kinases using an antibody array described in “Material and methods”. Bar graphs represent the expression of 
pS473-AKT, pT308-AKT, pS6, pErk1/2, pSTAT1 and pSTAT3. B. Expression of pAKT, AKT, pERK1/2, Erk1/2, pS6, S6 and pSTAT3 
in BT549 and HS578T; and effect of EC-70124 at 500 nM. Cell lysates were prepared and the activation state of the mentioned proteins 
using Western blot analysis. GAPDH was used as a loading control. Antibodies used are described in “Material and methods”. C. EC-70124 
kinase activity was profiled at 100 nM on a 169 kinase panel using a mobility shift assay at 1 mM ATP concentration for all kinases. A 
detailed description is given in “Material and methods”.
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Figure 3: Cell cycle analyses and effect on apoptosis of EC-70124. A, B. Effect of EC-70124 on cell cycle in HS578T, MDA-
MB-231 and BT549 (A) and graphical representation (B) Cells were cultured in DMEM 10% FBS and treated with 500 nM EC-70124. Cell 
cycle progression was examined after 12 and 24 hours of treatment by flow cytometry using propidium iodide DNA staining. The histogram 
(B) shows the mean percentage of cells in different phases of cell cycle after 12 and 24 hours of treatment. C. Apoptotic effect of EC-70124 
in HS578T, MDA-MB-231 and BT549. Cells were stained with Annexin V after 24 and 48 hours of treatment. The histogram represents the 
mean percentage of cells positive or negative for Annexin V staining. D. Induction of apoptosis with EC-70124 (500 nM) in the presence 
or absence of the pancaspase inhibitor Z-VAD-FMK. MDA-MB-231, HS578T and BT549 were cultured in DMEM 10% FBS and treated 
with 500 nM EC-70124 for 24 hours with and without the inhibitor. The histogram represents the mean percentage of cells positive or 
negative to Annexin V staining. E. Evaluation of PARP cleavage by Western blotting in HS578T, BT549 and MDA-MB-231 after treatment 
with EC-70124 at 6, 12 and 24 hours. GADPH was used as a loading control. The antibody used is described in “Material and methods”.
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with these agents. In general, administration of EC-70124 
with vinorelbine, carboplatin and docetaxel increased the 
anti-proliferative effect of each agent given alone (data not 
shown). To identify synergistic interactions we combined 
several doses of EC-70124 in the nanomolar range with 
doses of these agents around or below the IC50 in BT549, 
HS578T and MDA-MB-231. For this purpose we used the 
Chou-Talalay algorithm for combination index analysis 
[27]. Combinations with vinorelbine were antagonistic 
in MDA-MB-231 and BT549, and only additive for some 
doses in HS578T (Figure 6A). By contrast most doses for 
docetaxel and carboplatin were strongly synergistic or 
additive in the three cell lines (Figure 6A). The strongest 
synergism for the three cell lines was observed with the 
combination of EC-70124 with docetaxel. These findings 
were confirmed by clonogenic analyses using docetaxel 
and carboplatin. In HS578T, BT549 and MDA-MB-231 
the number of colonies formed were reduced with the 
combined treatments compared with agents given alone 
(Supplementary Figure S1C).
Given the fact that docetaxel and carboplatin 
were synergistic, we evaluated the effect on apoptosis 
of the combination of these agents with EC-70124. 
The administration of EC-70124 with docetaxel and 
Figure 4: Gene-set enrichment analyses of EC-70124. A, B, C, D. Network representation of enriched gene-sets (p-value <= 0.025 
and a FDR < 0.25), deregulated by EC-70124 at 500 nM including gene-sets associated with DNA damage, translation and regulation of 
gene expression (A), cell mesenchymal development and regulation morphogenesis of stem cell differentiation (B), EMT phenotype (C), 
adhesion, migration and cell proliferation (D) The red nodes (circles) are gene sets (pathways) significantly enriched in genes up-regulated 
in the EC-70124 treated samples, and the blue nodes are significantly enriched in genes down-regulated. Gray edges are lines that connect 
2 gene sets if they contain overlapping genes. Gene sets connected by multiple edges form a cluster also called a module because they 
represent a similar biological process.
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carboplatin to BT549 and HS578T clearly induced 
apoptosis at 48 hours (Supplementary Figure S1D). These 
findings suggest that the addition of some chemotherapies 
to EC-70124 augmented the cell death obtained with the 
kinase inhibitor.
In vivo evaluation and pharmacodynamic/
pharmacokinetic analyses
Finally we explored the effect of the combination of 
EC-70124 with carboplatin and docetaxel in xenografted 
mice. Doses of EC-70124 were reduced to 14 mg/kg 
alone or in addition to docetaxel and carboplatin both 
given at 15 mg/kg ip weekly for 3 consecutive weeks. At 
this dose, EC-70124 showed less activity than at a higher 
dose, but in the same range as carboplatin alone or the 
combination EC-70124 + carboplatin. Docetaxel clearly 
inhibited tumor growth and the combination of EC-70124 
with docetaxel reduced tumor volume in a statistically 
significant manner compared with docetaxel alone (Figure 
6B). No differences in mice weight were observed among 
different groups (data not shown).
To explore the pharmacodynamic effect of EC-
70124 in vivo, we treated mice injected with MDA-
MB-231, and sacrificed the animals at different time 
points after iv administration of EC-70124 alone. In the 
extracted tumors we observed a clear reduction of pS6 and 
pSTAT1 at 30 minutes. pSTAT3 was also slightly affected. 
Induction of pγH2AX, as a marker of DNA damage, was 
observed at 60 minutes (Figure 6C). No degradation of 
Figure 5: Effect of EC-70124 of migration, expression of stem-cell markers, and induction of DNA damage and 
activation of gene response. A. Effect of EC-70124 on cell migration. HS578, BT549T and MDA-MB-231 were treated with EC-70124 
at 500 nM and photographs were taken at 24 hours. Dasatinib at 100 nM were used as a control for inhibition of migration. B. Expression 
of CD44, CD49f, CD133 and ALDH1 after treatment with EC-70124 measured by flow cytometry in MDA-MB-231, HS578T and BT549. 
The histogram represents the percentage of positive cells. C. Fold change of genes related to DNA damage in treated versus untreated 
MDA-MB-231 cells. Red and blue colors represent the level of gene expression at greater than mean, and lower than mean, respectively. 
The numeric scale indicates the fold change of expression of each gene in each sample with respect to its mean expression value across all 
samples. Gene expression analyses is described in “Material and methods”. D. Representation of the transcription level of selected genes 
related to DNA damage in untreated and treated MDA-MB-231 cells (500 nM), at different time points (6, 12, 24 hours) measured by qRT-
PCR. E. Effect of EC-70124 on p-H2AX, p-P53 and p-Chk2 in HS578T, BT549 and MDA-MB-231. Cells were treated with EC-70124 
(500 nM) and mentioned proteins were evaluated by Western-blot. Antibodies used are described in “Material and methods”.
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Figure 6: Combinational studies in vitro and in vivo; and pharmacokinetic and pharmacodynamic evaluation. A. Effect 
of the combination of EC-70124 and standard of care drugs used in TNBC on cell proliferation. HS578T, BT549 and MDA-MB-231 cells 
were treated at the indicated concentrations of EC-70124, vinorelbine, carboplatin and docetaxel, alone and in combination, and their MTTs 
values were calculated. Combination indexes for the different drug combinations were obtained using CalcuSyn program and plotted. B. In 
vivo antitumor action of EC-70124 with docetaxel and carboplatin Nude mice were injected with MDA-MB-231. When tumors reached 200 
mm3 animals were treated with drugs alone or in combination, at the mentioned doses described in “Material and methods”. Data represent 
the mean +/− s.d. *P < 0.05, ***P < 0.001. C. Effect of EC-70124 on expression of p-S6, p-STAT1, p-STAT3, p-H2AX, PCNA and PARP 
in mice tumors. Animals were treated for 30, 60 and 120 minutes with EC-70124 (18 mg/kg iv) and activation of the indicated proteins 
were analyzed by Western-blotting. GAPDH was used as a loading control. D. EC-70124 accumulation in xenografted tumor: 4 nu/nu mice 
implanted with MDA-MB-231 were treated intravenously with 18 mg/Kg EC-70124, after the time specified, two tumors per time point 
were processed for LC-MS pharmacokinetics analysis. E. Phamacokinetic profile of EC-70124 administered by intravenous bolus injection 
(20 mg/Kg) in CD1 mice, each point represents the average of 3 mice plasma measurements, 1 ng/mL equals 2.2 nM EC-70124.
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PARP was observed and a slight reduction of PCNA, a 
marker of proliferation was identified at short times (we 
used the leukemic cell K562 treated with doxorubicin as 
a positive control for PARP degradation; Supplementary 
Figure S2A). These data confirm the findings observed 
in our biochemical studies in cell lines showing that EC-
70124 reduced pS6 and STAT1/STAT3, in addition to an 
induction of DNA damage. In addition, we treated animals 
with EC-70124 (18 mg/kg iv) for 24 hours and evaluated 
pS6, Ki67 and TUNEL by immunohistochemistry. We 
observed a clear reduction of pS6, Ki67; and an induction 
of apoptosis (Supplementary Figure 3A, 3B).
In parallel we evaluated the concentration of the 
drug in two resected tumors per time point. Figure 6D 
shows time-dependent accumulation, reaching over 
1000 ng/g (>2.2 μM) well above levels used in successful 
cell line experiments. Finally, by using another set of 
animals (healthy CD1 mice) we did a pharmacokinetic 
evaluation of EC-70124 at 20 mg/kg. As can be seen in 
Figure 6E, EC-70124 shows plasma levels well above 
needed for therapeutic action. The pharmacokinetic profile 
was typical of iv administration, with Cmax >25 μM at 
5 min and the levels going exponentially down over time, 
at 1 h 12 μM, at 4 h 4.5 μM and 8 h 2.2 μM and at 24 h 
100 nM. The area under the curve (AUC) was 33 μg/mL/h 
and the half life 3.1 h.
DISCUSSION
The prognosis of TNBC patients is poor due to the 
limited therapeutic options and the lack of specific targeted 
agents [28]. Given the importance of protein kinases 
including RTKs or downstream mediators in this subtype 
of breast cancer, we explored the antitumor activity and 
mechanism of action of the novel kinase inhibitor EC-
70124. In addition, as basal-like tumors show an increase 
in proliferation, metastatic spreading, early relapse and 
an impairment of DNA repair mechanisms, it would be 
desirable to identify a drug that would affect some of these 
deregulated functions.
Natural products are well known by their pleiotropic 
mechanism of action. The combinatorial biosynthesis of 
Rebeccamycin and Staurosporine gene pathways led to 
EC-70124, a hybrid indolocarbazole analog obtained by 
recombinant fermentation [24]. Treatment with EC-70124 
reduced proliferation and colony formation in several 
TNBC cell models. Studies in animals showed the anti-
tumor activity of EC-70124 in vivo with no evidence of 
relevant toxicity. When the mechanism of action was 
evaluated, we observed that administration of EC-70124 
induced DNA damage at short times measured by the 
phosphorylation of γH2AX and other proteins including 
the phosphorylated forms of p53 and Chk2, all of them 
downstream effectors of ATM and ATR in response to 
DNA insults [25, 26, 29].
In TNBC several membrane and intracellular 
kinases are concomitantly activated suggesting that 
combinatorial strategies or inhibition of central signaling 
nodes could be more effective than single target inhibition 
[19, 21]. The PI3K/mTOR and the MAPK pathway are 
commonly phosphorylated in this tumor type [19]. Less 
frequent activated kinases include STAT1, STAT3 or SRC, 
among others [19]. Our data corroborated these findings 
and furthermore describe the kinase inhibitory profile 
of EC-70124 on these routes. EC-70124 produced a 
decrease in phosphorylation of the mTORC1 downstream 
component pS6. Interestingly, inhibition of the mTORC2 
route by EC-70124 resulted distinct in BT549 and 
HS578T. In the latter cell line, treatment with the drug 
inhibited AKT phosphorylation at serine 473, a site 
whose phosphorylation is due to the activity of mTORC2 
complexes. In contrast, S473 phosphorylation was 
unaffected by EC70124 in BT549 cells, indicating that 
the mTORC2-inhibiting capability of the drug may differ 
among distinct cell lines. The effect on the JAK pathway 
was confirmed when we evaluated the kinase profile of 
the drug. In our experiments doses of the drug in the 
nanomolar range were able to produce growth inhibition 
in a panel of TNBC cell lines at the same dose that 
inhibited efficiently the mentioned routes. Among those 
the PI3K/mTOR seems to be of substantial importance. In 
previous experiments inhibition of this pathway in TNBC 
produced a profound antitumor activity in cell lines and 
in xenografted tumors [19]. Those findings helped guide 
the development of inhibitors against this pathway in the 
clinical setting [19, 30]. EC-70124 inhibited other relevant 
pathways such as the JAK/STAT; route that is involved in 
the genesis of breast tumors with stem cell properties, a 
finding that is in line with the down-regulation of gene-sets 
related to regulation of stem cell differentiation and the 
reduction of several stem-cell markers measured with flow 
cytometry [13]. Of note, no effect on RTK was observed 
as there was a minimal constitutive phosphorylation in 
the cell lines. The inhibition of the mentioned proteins 
were also confirmed in pharmacodynamic experiments 
showing that the drug reached the tumor at early time 
points. The presence of the drug was evaluated in two 
tumors per time point showing a remarkable exposure. 
Finally pharmacokinetic experiments confirmed a tipical 
iv elimination curve with concentrations of the drug above 
the micromolar range at 8 hours.
Gene set enrichment analyses (GSEA) revealed 
deregulation of many cellular functions including cell 
morphogenesis; regulation of stem cell differentiation; 
EMT phenotype, migration and DNA damage, among 
others. As a multikinase inhibitor with effect on different 
cancer-relevant kinases, it is expected to observe the 
inhibition of several functions. Among them, cell 
migration was inhibited by the drug in the same amount as 
other kinase inhibitors with known capabilities to reduce 
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this function. Several markers used to identify populations 
with stem cell characteristics, were also reduced after 
treatment with EC-70124 [13, 31]. Furthermore, the JAK/
STAT pathway, that is required for the growth of stem cell-
like breast cancers [13], was also inhibited by EC-70124 
in our biochemical studies.
DNA repair was one of the functions altered by the 
drug. At longer times we observed an increased expression 
of genes involved in DNA repair; genes that probably 
were synthesized in response to a DNA insult. This 
observation was confirmed by qPCR of the upregulated 
genes including BRCA2, LIG4, GADD45 or XPA, 
among others. Although induction of DNA damage is an 
infrequent effect of kinase inhibitors, we have observed 
before that the combination of dasatinib, a multi-TK 
inhibitor, with trastuzumab, an anti-HER2 antibody, 
produced a similar effect on DNA [32].
Physiological repair of DNA damage requires 
cells to arrest [17]. In our experiment we observed by 
flow cytometry how treatment with EC-70124 induced 
an arrest in G2/M. Induction of apoptosis evaluated by 
Annexin V staining was observed at 48 hours suggesting 
that some cells were unable to repair their DNA and finally 
led to cell death. This induction of apoptosis was largely 
independent of the activation of caspases. In addition, 
combination of EC-70124 with chemotherapy increase 
apoptosis compared with each agent given alone.
When combined with chemotherapies, EC-70124 
produced a synergistic effect with docetaxel opening the 
door for potential combinations with these agents in the 
clinical setting. Taxanes are one of the gold standards in 
the treatment of this disease. In line with this, the studies 
in animals showed that EC-70124 increased the antitumor 
effect of docetaxel, compared with the effect of each agent 
given alone. A much limited effect was observed with the 
combination of carboplatin.
Globally, our article describes a novel multi-
kinase inhibitor with a remarkable antitumor activity in 
TNBC. The pleiotropic nature of the effects of this drug, 
which affects cell cycle progression, migration or stem-
like properties of TNBC cells offers the possibility of 
acting on all those oncogenic pathways using a single 
agent. Moreover, its synergistic effect with drugs that 
are commonly used to treat TBNC patients opens the 
possibility for the development of EC-70124 alone or in 
combination with those drugs in the clinical setting.
MATERIALS AND METHODS
Cell culture and drug compounds
HS578T, BT549, MDA-MB-231 and HCC3153 
breast cancer cell lines were provided by Drs J Losada 
and A Balmain (originally from Dr. JW Gray’s Laboratory, 
who in turn obtained them from the ATCC or from 
collection development in the laboratories of Drs S Ethier 
and A Gazdar to avoid errors occurring when obtained 
through ’second-hand’ sources). In addition cells were 
analyzed by STR at the molecular biology unit at the 
Salamanca University Hospital. Cell lines were maintained 
in DMEM (HS578T, BT549, MDA-MB-231) and RPMI 
(HCC3153) containing 10% fetal bovine serum (FBS), 
with 100 U/mL penicillin, 100 μg/mL streptomycin and 
2 mM L-glutamine, respectively. The cell culture medium 
and supplements were obtained from Sigma Aldrich (St. 
Louis, MO). The multi-kinase inhibitor EC-70124 was 
prepared via a proprietary process by Entrechem S.L. 
(Oviedo, Spain). Chemotherapeutic agents (Docetaxel, 
Carboplatin and Vinorelbine) were purchased from 
Selleckchem.
Cell proliferation studies: MTT assays, 
matrigel-embedded culture experiments 
and clonogenic assays
The effect of drugs on cell proliferation was 
assessed using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 
5 diphenyltetrazolium bromide) screening assay. This 
experiment is based on the ability of living cells to convert 
MTT, a yellow tetrazole, into a purple colored formazan 
product with an absorbance maximum near 570 nm. 
Thus, a decrease in the amount cells amount will result 
in a reduced purple colouring. HS578T, BT549, MDA-
MB-231 and HCC3153 cells were plated at 10,000 cells 
per well in 48-multiwell plates and cultured overnight in 
DMEM and RPMI + 10% FBS. The next day, cells were 
treated for three days with increasing concentrations 
of EC-70124 alone or in combination with various 
chemotherapeutics to plot the dose–response curves and 
for synergy studies, respectively. In parallel, the IC50 
value was determined by cell treatment with increasing 
amounts of EC-70124 at three-time points (24 h, 48 h 
and 72 h of incubation). After drug administration, the 
medium was replaced with 400 μL of fresh medium 
DMEM without phenol red containing MTT (0.5 μg/μL) 
and incubated for 45 minutes at 37°C. The medium was 
then removed and 200 μL of dimethylsulfoxide (DMSO) 
were added to each well. The plate was agitated in the dark 
for 5 minutes to dissolve the MTT-formazan crystals. The 
absorbance of the samples was recorded at 562 nm (555–
690) in a multiwell plate reader (BMG labtech). Results 
were plotted as the mean values of quadruplicates from a 
representative experiment that was repeated at least two 
independent times.
For drug combination studies, synergy was 
confirmed using Calcusyn Version 2.0 software (Biosoft, 
Ferguson, MO) by determining combinational index (CI) 
based on the algorithm reported by Chou and Talalay [27]. 
Values <1 represent synergistic effect on cell proliferation 
of the 2 drugs, values equal to 1 indicate additive effect 
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of the drugs, and values >1 represent an antagonistic 
effect. Combination index values from three independent 
experiments were generated and plotted.
For three-dimensional cell culture experiments, 
HS578T, BT549 and MDA-MB-231 cells were grown 
in DMEM supplemented with 10% FBS. Following 
passage, cells were trypsinized (0.5 g porcine trypsin and 
0.2 g EDTA 4Na, purchased from Sigma Aldrich) and 
resuspended in growth medium containing 2% Matrigel. 
Then, cells were seeded at a density of 12.500 cells/ml in a 
48-multiwell plate containing an underlying approximately 
1 mm thick bed of Matrigel and incubated at 37°C. Next 
day, cells were treated with EC-70124 and cultured for 
7 days. The assay included the daily visualization of cells 
under a light microscope to monitor the phenotype.
For clonogenic studies, cells were seeded at a 
density of 500,000 cells in a 100 mm culture dishes, and 
treated, the next day, with with EC-70124 (300 nM), 
docetaxel (0.5 nM), EC-70124 + docetaxel, carboplatin 
(20 μM) and EC-70124 + Carboplatin. After 24-hours 
treatment, cells were trypsinized, resuspended in 5 ml 
of complete growth medium to perform serial dilutions 
1/10 and seeded, in triplicate, in 6-multiwell plates for 10 
days. Then, the medium was removed and the number of 
colonies were determined.
Wound-healing assay for cell migration
HS578T, BT549 and MDA-MB-231 cells were plated 
at a density of 300,000 cells/60 mm dish and maintained 
overnight in DMEM + 10% FBS. Following incubation, 
culture medium was removed and a wound in the cell 
monolayers was generated by scratching with a 200-μl 
pipette tip. Photographs were taken of the initial wound for 
comparison. Then, DMEM + 10% FBS was added and cells 
were treated for 48 hours with either 500 nM EC-70124 or 
100 nM Dasatinib, as a negative control. Cell migration was 
visualized at ×10 magnification and photographed. Each 
experiment was completed in duplicate.
Cell cycle and apoptosis detection assays
For cell cycle analysis, HS578T, BT549 and 
MDA-MB-231 cells were plated at a density of 500,000 
cells/100 mm dish and maintained overnight in DMEM 
+ 10% FBS. Cells were then treated with 500 nM of 
EC-70124 for 24 hours. After drug treatment, cells 
were trypsinized, fixed in ice cold 70% ethanol for 
30 minutes and subsequently centrifuged at 5000 rpm for 
5 minutes. Cell pellets were washed in PBS + 2% BSA 
and treated with Propidium iodide/RNAse staining 
solution (Immunostep S.L., Salamanca, Spain) in the dark 
for 1 hour at 4°C, and analyzed then on FACSCanto II 
flow cytometer (BD Biosciences). The percentage of each 
cell cycle phase was determined by plotting DNA content 
against cell number using the FACS Diva software.
For Annexin V/PI experiments, 500 nM EC-70124 
treated cells (at a density of 500,000 cells/100 mm dish) 
were washed twice with PBS, and stained with 5 μl of 
Annexin V-DT-634 (Immunostep S.L., Salamanca, Spain) 
and 3 μl of Propidium iodide (10 mg/ml) in 1x Binding 
Buffer (10 mM HEPES, pH 7.4, 140 mM NaOH, 2.5 mM 
CaCl2) for 1 hour at room temperature in the dark. The 
apoptotic cells were determined using a FACSCanto II 
flow cytometer (BD Biosciences). Both early apoptotic 
(Annexin V-positive, PI-negative) and late (Annexin 
V-positive and PI-positive) apoptotic cells were included 
in cell death determinations.
Preparation of cell extracts and western-blotting
HS578T and BT549 cells were plated at a density 
of 500,000 cells/100 mm dish, maintained overnight in 
DMEM + 10% FBS, and treated later with EC-70124 at 
500 nM for 6, 12 and 24 hours. After treatment, cells were 
washed with cold PBS and lysed in cold lysis buffer (20 
mM Tris–HCl [pH 7.0], 140 mM NaCl, 50 mM EDTA, 
10% glycerol, 1% Nonidet P-40, 1 μM pepstatin, 1 μg/
mL aprotinin, 1 μg/mL leupeptin, 1 mM phenylmethyl 
sulfonyl fluoride, 1 mM sodium orthovanadate). Then, 
insoluble material was removed by centrifugation. 
The protein concentration was determined using BCA 
(Bicinchoninic acid) protein assay kit (Sigma Aldrich).
For Western-blotting, 50 μg protein was resolved 
by 6%–15% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred 
to polyvinylidene difluoride membranes (Millipore 
Corporation). Blots were blocked in 1x Tris-buffered 
saline (TBS, 100 mM Tris [pH 7.5], 150 mM NaCl, 0.05% 
Tween 20) containing 0.05% Tween 20 and 1% of bovine 
serum albumin for 1 hour and then incubated overnight 
with the following primary human monoclonal/policlonal 
antibodies: anti-pS473-AKT, anti-pH2AX (BD Biosciences), 
anti-pERK1/2, PARP (Santa Cruz Biotechnology), 
anti-pS6, anti-pSTAT3, anti-pSTAT1, anti-pT308-AKT 
(Cell Signalling Technology). Protein-bound primary 
antibodies were detected using respective horseradish 
peroxidase-coupled secondary antibodies (anti-rabbit 
for polyclonal and anti-mouse for monoclonal, obtained 
from Santa Cruz Biotechnology) diluted 1:5,000 in 1x 
TBS containing 0.05% Tween and incubated for 1 hour at 
room temperature. Protein bands were detected using ECL 
Plus Western Blotting Detection System (GE Healthcare, 
Buckinghamshire, United Kingdom).
Phospho-kinase antibody array and 
immunohistochemistry
To evaluate whether EC-70124 treatment causes a 
change in the kinase phosphorylation profiling of human 
breast cancer cell, two different commercial arrays, the 
human phospho-RTK array kit (# ARY001, R&D Systems, 
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Abingdon, UK) and the PathScan RTK Signaling Antibody 
Array Kit (# 7982, Cell Signaling Technology) were used. 
The array kits allows for the simultaneous detection of 
receptor tyrosine kinases and downstream signaling nodes, 
when phosphorylated at tyrosine or other residues. Target-
specific capture antibodies, biotinylated protein (positive 
control) and non-specific IgG (negative control) have 
been spotted in duplicate onto the array membrane. Cell 
lysates were diluted to a total protein concentration and 
incubated with the RTK arrays according to manufacturer’s 
instructions. After binding the domain of both phosphorylated 
and unphophorylated tyrosine kinases, unbound material 
was washed away. A pan anti-phospho-tyrosine antibody 
conjugated to horseradish peroxidase (HRP) was used to 
detect phosphorylated tyrosines on activated receptors by 
chemiluminescence. Quantitation of the different RTKs and 
cell signaling intermediates in the human phospho-RTK array 
kit was performed using the Quantity One analysis software 
(Bio-Rad, CA, USA) and expressed as the pixel density (OD/
mm2). The pixel density of the background was subtracted 
from the pixel density of each spot, and the average of 
duplicate spots was determined. Next, Signal intensity was 
calculated by the normalization of mean pixel density in 
each spot against the pixel density of the positive control. 
Significance was determined using a cut-off point of density 
signal higher than 0.6.
For the immunohistochemistry evaluation, tumour 
samples from mice were obtained and fixed with 
formaldehyde 24 hours at room temperature. After the 
samples were embedded in paraffin, they were cut into 
thin slices and mounted on slides for subsequent analysis. 
The immunohistochemistry for ki67, pS6 were performed 
as described [33, 34] and TUNEL was performed 
following the manufacturer’s instructions (In situ cell 
Death Detection Kit, AP, Roche).
Microarray analysis of mRNA
MDA-MB-231 cells were grown in DMEM with 
10% of FBS and added to a final concentration of 500,000 
cells/plate. Next day cells were treated with 500 nM EC- 
70124 for 24 h. Total RNA from 3 independent control 
samples and 3 independent treated cells was extracted and 
purified using the RNeasy Mini Kit (Qiagen). Double-
stranded cDNA and biotinylated cRNA were synthesized 
using a T7 polyT primer and the BioArray RNA labeling 
kit (Enzo Life Sciences, Farmingdale, NY), respectively. 
The labeled RNA was fragmented and hybridized 
to human oligonucleotide arrays (Human Gene ST 
Arrays) (Affymetrix, Santa Clara, CA) according to the 
manufacturer’s instructions. Affymetrix CEL files were 
imported into the dChip software (Dana Farber Cancer 
Institute, Boston, MA): normalization of all arrays was 
done using a pair-wise rank invariant probe method and 
expression level of each probeset was calculated using the 
model-based expression index (MBEI).
Gene-set enrichment analysis
The MBEI data for all probesets were further 
imported into the GSEA software [26] to perform gene-
set enrichment analysis using 2000 gene-set permutations, 
minimum gene-set size of 5, maximum gene-set size of 500 
and t-test as the scoring metric. The gene-sets included in 
the GSEA analyses were obtained from KEGG, MsigDB-c2, 
NCI, Biocarta, IOB, Netpath, HumanCyc, Reactome and 
the Gene Ontology (GO) databases, updated August 2014 
(http://baderlab.org/GeneSets). EnrichmentMap (version 
2.0, automatic labelling option, Cytoscape 3.2.1) was used 
to visualize enriched gene-sets with a nominal p-value < 
0.025 and a False Discover Rate < 0.25.
Quantitative reverse-transcription PCR 
(qRT-PCR)
Untreated and EC-70124-treated cells were collected 
and mRNA levels of the indicated genes were determined 
by quantitative reverse- transcription PCR. Briefly, total 
RNA was obtained from cells using RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to manufacturer’s 
instruction. After extraction, concentration and purity were 
determined using a NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific, USA) and, subsequently, 3 μg 
of total RNA was reversely transcribed using RevertAid 
H Minus First Strand cDNA syntesis Kit (Thermo Fisher 
Scientific, USA) in a thermocycler (Bio-Rad) under the 
following reaction conditions: 65°C for 5 min, 42°C for 60 
min and 70°C for 10 min. The cDNAs were then subjected 
to a real-time PCR analysis using Fast SYBR Green Master 
Mix in StepOnePlus Real-Time PCR system (Applied 
Biosystems) according to the manufacturer’s instructions. 
Primer sequences for the genes are shown in Supplementary 
Table S3. An initial step was performed at 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 sec and finished by 
60°C for 1min. each sample was analyzed in triplicates and 
cycle threshold (Ct) values of transcripts was determined 
using StepOne Software v.2.1. The ΔCt values were 
calculated using GAPDH as reference. Untreated cells were 
used as control to calculate the ΔΔCt value and to determine 
the X-fold mRNA expression.
Xenograft studies
Mice were handled at the animal facility following 
legal guidelines. Female BALB/cAnNRi-Foxn1nu/Foxn1nu 
mice, 5 weeks old were obtained from Janvier Labs. After 10 
days quarantine, 2–5 × 106 MDA-MB-231 cells in 100 μL 
of DMEM with 20% Matrigel were injected into the 
mammary fat pads of mice. Two weeks after the injection, 
mice were randomly assigned into two groups (with equal 
average tumor volumes before initiation of treatments) 
control vehicle (manufacturer recommendations) (n = 5) 
and EC-70124 + vehicle (n = 5). After approximately 
Oncotarget27936www.impactjournals.com/oncotarget
2 weeks, when tumors reached a volume of 100 mm3 
treatment was initiated. Animals were inhalatorily 
anaesthetized and then treated with EC70124 i.v. (18 mg/
kg) every three days. For combinatory studies, when tumors 
reached a volume of 200 mm3 treatment was initiated, in 
this case, we used EC-70124 (14 mg/kg) every three days 
alone or in combination with carboplatin (15 mg/kg) or 
docetaxel (15 mg/kg) ip weekly for 3 consecutive weeks 
(n = 5 for all groups). Tumors diameters were measured 
every three days and tumor volumes were calculated using 
the following formula: V = (L × W2)/2, where V = volume 
(cubic millimeters), L = length (millimeters) and W = width 
(millimeters). Mice were killed by CO2 inhalation.
Pharmacokinetics
Healthy CD-1 female mice were dosed orally with 
EC-70124 (18 mg/Kg). Blood was collected at eight 
time-points between 5 min and 24 h. Each time point 
represented the average of 3 mice. Serum was diluted 
with 1 volume of methanol and centrifuged to eliminate 
any insoluble precipitate. The supernatant was then used 
to measure EC-70124 by LC-MS.
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